Cargando…
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and radiation offer limited benefit, and systemic chemotherapy remains the primary treatment modality for the majority of patients. Vascular endothelial growth factor (VEGF) and its receptor have been recognized as import...
Autores principales: | Levin, Pavel A, Dowell, Jonathan E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391166/ https://www.ncbi.nlm.nih.gov/pubmed/28435296 http://dx.doi.org/10.2147/OTT.S113598 |
Ejemplares similares
-
Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
por: Akamine, Takaki, et al.
Publicado: (2018) -
Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date
por: Kao, Christina C, et al.
Publicado: (2019) -
Modern management of malignant pleural mesothelioma
por: Patel, Shivani C, et al.
Publicado: (2016) -
Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight
por: Xu, Duo, et al.
Publicado: (2020) -
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado, Álvaro, et al.
Publicado: (2018)